Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion.

Recurrence and metastasis result in a poor prognosis for breast cancer patients. Recent studies have demonstrated that microRNAs (miRNAs) play vital roles in the development and metastasis of breast cancer. In this study, we investigated the therapeutic potential of miR-34a in breast cancer. We found that miR-34a is downregulated in breast cancer cell lines and tissues, compared with normal cell lines and the adjacent nontumor tissues, respectively. To explore the therapeutic potential of miR-34a, we designed a targeted miR-34a expression plasmid (T-VISA-miR-34a) using the T-VISA system, and evaluated its antitumor effects, efficacy, mechanism of action, and systemic toxicity. T-VISA-miR-34a induced robust, persistent expression of miR-34a, and dramatically suppressed breast cancer cell growth, migration, and invasion in vitro by downregulating the protein expression levels of the miR-34a target genes E2F3, CD44, and SIRT1. In an orthotopic mouse model of breast cancer, intravenous injection of T-VISA-miR-34a:liposomal complex nanoparticles significantly inhibited tumor growth, prolonged survival, and did not induce systemic toxicity. In conclusion, T-VISA-miR-34a lead to robust, specific overexpression of miR-34a in breast cancer cells and induced potent antitumor effects in vitro and in vivo. T-VISA-miR-34a may provide a potentially useful, specific, and safe-targeted therapeutic approach for breast cancer.

[1]  C. Croce,et al.  Targeting microRNAs in cancer: rationale, strategies and challenges , 2010, Nature Reviews Drug Discovery.

[2]  R. Weinberg,et al.  A Perspective on Cancer Cell Metastasis , 2011, Science.

[3]  V. Ganapathy,et al.  SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancer. , 2011, Cancer research.

[4]  Päivi Heikkilä,et al.  MiR-34a Expression Has an Effect for Lower Risk of Metastasis and Associates with Expression Patterns Predicting Clinical Outcome in Breast Cancer , 2011, PloS one.

[5]  Douglas B. Evans,et al.  Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. , 2007, Cancer cell.

[6]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[7]  Michael A. Beer,et al.  Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. , 2007, Molecular cell.

[8]  M. Xiong,et al.  Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells , 2002, Oncogene.

[9]  Guy Leclercq,et al.  p53 and breast cancer, an update. , 2006, Endocrine-related cancer.

[10]  D. Weaver,et al.  The TNM staging system and breast cancer. , 2003, The Lancet. Oncology.

[11]  D. R. Coombe,et al.  Expressed luciferase viability assay (ELVA) for the measurement of cell growth and viability. , 1998, Journal of immunological methods.

[12]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[13]  Jason L. Townson,et al.  Ineffectiveness of Doxorubicin Treatment on Solitary Dormant Mammary Carcinoma Cells or Late-developing Metastases , 2003, Breast Cancer Research and Treatment.

[14]  P. Steeg.  Tumor metastasis: mechanistic insights and clinical challenges , 2006, Nature Medicine.

[15]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[16]  P. Pandolfi,et al.  Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis , 2010, Nature Cell Biology.

[17]  Eva E. Rufino-Palomares,et al.  MicroRNAs as Oncogenes and Tumor Suppressors , 2013 .

[18]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[19]  Stefano Piccolo,et al.  MicroRNA control of signal transduction , 2010, Nature Reviews Molecular Cell Biology.

[20]  F. Gao,et al.  The impact of miR‐34a on protein output in hepatocellular carcinoma HepG2 cells , 2010, Proteomics.

[21]  C. Deng,et al.  Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. , 2008, Molecular cell.

[22]  R. Agami,et al.  MicroRNA regulation by RNA-binding proteins and its implications for cancer , 2011, Nature Reviews Cancer.

[23]  S. Edge,et al.  Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. , 2003, The Surgical clinics of North America.

[24]  C. Croce,et al.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  K. Kelnar,et al.  The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. , 2011, Nature medicine.

[26]  H. Strey,et al.  Improved DNA: liposome complexes for increased systemic delivery and gene expression , 1997, Nature Biotechnology.

[27]  Sharon J. Diskin,et al.  A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene , 2008, Molecular Cancer Research.

[28]  F. Slack,et al.  MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy , 2011, Nature Reviews Cancer.

[29]  C. Croce,et al.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. , 2007, Cancer research.

[30]  J. Vieira,et al.  New pUC-derived cloning vectors with different selectable markers and DNA replication origins. , 1991, Gene.

[31]  C. Steer,et al.  miR-34a Regulates Mouse Neural Stem Cell Differentiation , 2011, PloS one.

[32]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[33]  M. Zöller.  CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? , 2011, Nature Reviews Cancer.

[34]  Dirk Winkler,et al.  miR-34a as part of the resistance network in chronic lymphocytic leukemia. , 2008, Blood.

[35]  Bernat Gel,et al.  miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. , 2009, Carcinogenesis.

[36]  S. Gambhir,et al.  Noninvasive imaging of enhanced prostate-specific gene expression using a two-step transcriptional amplification-based lentivirus vector. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  W. Woodward,et al.  BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. , 2011, Cancer cell.

[38]  Vieira Jeffrey,et al.  New pUC-derived cloning vectors with different selectable markers and DNA replication origins. , 1991 .

[39]  T. Hope,et al.  Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances Expression of Transgenes Delivered by Retroviral Vectors , 1999, Journal of Virology.

[40]  H. Gómez,et al.  Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone , 2010, Breast Cancer Research.

[41]  H. Hermeking.  The miR-34 family in cancer and apoptosis , 2010, Cell Death and Differentiation.

[42]  John D. Minna,et al.  Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery , 2009, PloS one.

[43]  Sanjiv S Gambhir,et al.  Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[44]  R. Bast,et al.  A novel hTERT promoter–driven E1A therapeutic for ovarian cancer , 2009, Molecular Cancer Therapeutics.